By Scientia Professor Vlado Perkovic

Journal articles

Perkovic V; Tuttle KR; Rossing P; Mann JFE; Idorn T, 2025, 'Response to the letter to the editor entitled “Semaglutide and kidney function: direct kidney protection or an artifact?”', Kidney International, 108, pp. 948 - 950, http://dx.doi.org/10.1016/j.kint.2025.07.008

Kim D; Woodward M; Lv J; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Perkovic V; Zhang H; Wong MG, 2025, 'Sex Differences Across Corticosteroid Response and Outcomes in IgA Nephropathy', Kidney International Reports, 10, pp. 3527 - 3534, http://dx.doi.org/10.1016/j.ekir.2025.07.041

Ketema DB; Wallace H; Hailu W; Badve SV; Ronksley P; Neuen BL; Pecoits-Filho R; Gallagher M; Kotwal S; Perkovic V; Joshi R; Jun M, 2025, 'Quality of care for people with chronic kidney disease: a systematic review and meta-analysis', BMJ Open, 15, http://dx.doi.org/10.1136/bmjopen-2025-102044

Beal B; Buizen L; Yeung EK; Heath L; Houston L; Cherney DZI; Jardine M; Pollock C; Arnott C; Kotwal SS; Heerspink HJL; Perkovic V; Neuen BL, 2025, 'Effects of SGLT2 inhibition on insulin use in CKD and type 2 diabetes: Insights from the CREDENCE trial', Nephrology Dialysis Transplantation, 40, pp. 1727 - 1735, http://dx.doi.org/10.1093/ndt/gfaf044

Oshima M; Buizen L; Jongs N; Levin A; Chertow GM; Wheeler DC; Heerspink HJL; Arnott C; Jardine MJ; Mahaffey KW; Pollock C; Herrington WG; Perkovic V; Neuen BL, 2025, 'Sodium-Glucose Cotransporter 2 Inhibition and Hospitalizations in Patients with CKD: A Meta-Analysis of Kidney Outcome Trials', Clinical Journal of the American Society of Nephrology, 20, pp. 1206 - 1214, http://dx.doi.org/10.2215/CJN.0000000771

Mazhar F; Fu EL; Faucon AL; Hjemdahl P; Mathisen J; Muhammad IF; Plunde O; Perkovic V; Tuttle KR; Carrero JJ, 2025, 'Systemic Inflammation and the Risks of Adverse Kidney Outcomes in Adults With Atherosclerotic Cardiovascular Disease', American Journal of Kidney Diseases, 86, pp. 314 - 323.e1, http://dx.doi.org/10.1053/j.ajkd.2025.04.011

Jeyaruban A; Bose B; Lee VW; Jardine M; Mallawaarachchi A; Ritchie A; Wong MG; Makris A; Badve SV; Siriwardana A; Yong K; Perkovic V; Kotwal S, 2025, 'Glomerular disease registry and biobank: design and baseline results', Internal Medicine Journal, 55, pp. 1301 - 1307, http://dx.doi.org/10.1111/imj.70056

Chatur S; Vaduganathan M; Fletcher RA; Perkovic V; Heerspink H; Arnott C; Pollock C; Mahaffey KW; Neal B; Jardine M; Solomon SD; Neuen BL, 2025, 'Canagliflozin reduces oral loop diuretic intensification in patients with type 2 diabetes: A participant-level pooled analysis of the CANVAS and CREDENCE trials', European Journal of Heart Failure, 27, pp. 994 - 1002, http://dx.doi.org/10.1002/ejhf.3586

Kim D; Neuen BL; Lv J; Hladunewich MA; Jha V; Hooi LS; Monaghan H; Fletcher RA; Billot L; Perkovic V; Zhang H; Wong MG, 2025, 'Corticosteroid Effects in IgA Nephropathy by Baseline Proteinuria and Estimated GFR', Kidney International Reports, 10, pp. 1886 - 1895, http://dx.doi.org/10.1016/j.ekir.2025.03.008

Nguyen TN; Yu J; Perkovic V; Jardine M; Mahaffey KW; Chow CK; Arnott C; Lindley RI, 2025, 'The Efficacy and Safety of Canagliflozin by Frailty Status in Participants of the CANVAS and CREDENCE Trials', Journal of the American Geriatrics Society, 73, pp. 1787 - 1796, http://dx.doi.org/10.1111/jgs.19444

Barratt J; Perkovic V; Rizk DV, 2025, 'Alternative Complement Pathway, Iptacopan, and IgA Nephropathy: The authors reply', New England Journal of Medicine, 392, pp. 1976, http://dx.doi.org/10.1056/NEJMc2503117

Lee MMY; Sattar N; Pop-Busui R; Deanfield J; Emerson SS; Inzucchi SE; Mann JFE; Marx N; Mulvagh SL; Poulter NR; Badve SV; Pratley RE; Perkovic V; Buse JB; McGuire DK, 2025, 'Cardiovascular and Kidney Outcomes and Mortality With Long-Acting Injectable and Oral Glucagon-Like Peptide 1 Receptor Agonists in Individuals With Type 2 Diabetes: A Systematic Review and Meta-analysis of Randomized Trials', Diabetes Care, 48, pp. 846 - 859, http://dx.doi.org/10.2337/dc25-0241

Greene T; Collier W; Haaland B; Zhang C; Badve SV; Caravaca-Fontán F; Del Vecchio L; Floege J; Hannedouche T; Imai E; Jafar TH; Lewis JB; Li PKT; Locatelli F; Maes BD; Neuen BL; Perrone RD; Schena FP; Toto R; Wanner C; Woodward M; Van Zuilen A; Heerspink HJL; Inker LA; Estacio RO; Hanratty R; Chalmers J; Parving HH; Appel GB; Canetta P; Brenner BM; Barrett B; Neal B; Mahafey KW; Neuen B; Johnson D; Perkovic V; Mahaffey KW; Jardine M; Fervenza F; Von Eynatten M; Goicoechea M; Verde E; Verdalles U; Arroyo D; Chapman A; Torres V; Yu A; Brosnahan G; Kam-Tao Li P; Chow KM; Szeto CC; Leung CB; Xie D; Hou FF; Dwyer J; Pohl M; Raz I; Hunsicker L; Becker GJ; Ihle BU; Kincaid-Smith PS; Kamper A; Katafuchi R; Vanacker A; Malfait T; Maschio G; Van Kruijsdijk R; Vernooij RWM; Kobayashi F; Makino H; Chan JCN; Passerini P; Andrulli S; Pozzi C; Casartelli D; Praga M; Trujillo H; Cavero T; Sevillano A; Ruggenenti P; Perna A; Carrara F; Gherardi G; Keane WF; Manno C; Haynes R; Herrington WG; Baigent C; Landray M; Rauen T; Seikrit C; Wied S; De Zeeuw D; De Jong PE; Saddelli M; Zucchelli P, 2025, 'Clinical Implications of Slope of GFR in Clinical Trials of CKD Progression', Clinical Journal of the American Society of Nephrology, 20, pp. 632 - 641, http://dx.doi.org/10.2215/CJN.0000000662

Koshino A; Heerspink HJL; Jongs N; Badve SV; Arnott C; Neal B; Jardine M; Mahaffey KW; Pollock C; Perkovic V; Hansen MK; Bakker SJL; Wada T; Neuen BL, 2025, 'Canagliflozin and iron metabolism in the CREDENCE trial', Nephrology Dialysis Transplantation, 40, pp. 696 - 706, http://dx.doi.org/10.1093/ndt/gfae198

Siriwardana A; Buizen L; Jun M; Kotwal S; Arnott C; Jardine MJ; Levin A; Heerspink HJL; Charytan DM; Pollock C; Perkovic V; Neuen BL, 2025, 'Cardiovascular, kidney and safety outcomes with canagliflozin in older adults: A combined analysis from the CANVAS Program and CREDENCE trial', Diabetes Obesity and Metabolism, 27, pp. 1972 - 1979, http://dx.doi.org/10.1111/dom.16190

Chan B; Varghese A; Badve SV; Pecoits-Filho R; Guedes M; Arnott C; Kozor R; O'Lone E; Jun M; Kotwal S; Block GA; Chertow GM; Solomon SD; Vaduganathan M; Perkovic V; Neuen BL, 2025, 'Systematic Review of the Effects of Iron on Cardiovascular, Kidney, and Safety Outcomes in Patients With CKD', Kidney International Reports, 10, pp. 1037 - 1049, http://dx.doi.org/10.1016/j.ekir.2025.01.029

Mahaffey KW; Tuttle KR; Arici M; Baeres FMM; Bakris G; Charytan DM; Cherney DZI; Chernin G; Correa-Rotter R; Gumprecht J; Idorn T; Pugliese G; Rasmussen IKB; Rasmussen S; Rossing P; Sokareva E; Mann JFE; Perkovic V; Pratley R, 2025, 'Cardiovascular outcomes with semaglutide by severity of chronic kidney disease in type 2 diabetes: the FLOW trial', European Heart Journal, 46, pp. 1096 - 1108, http://dx.doi.org/10.1093/eurheartj/ehae613

Siriwardana A; Smyth B; Jardine M, 2025, 'Waiver of informed consent in clinical research: a summary of contemporary guidelines and a resource for researchers', BMJ Open, 15, http://dx.doi.org/10.1136/bmjopen-2024-091896

Webster ER; Perkovic A; Neuen BL; Tuttle KR; Perkovic V, 2025, 'Effects of anti-inflammatory agents on clinical outcomes in people with chronic kidney disease: a systematic review and meta-analysis of randomized control trials', Clinical Kidney Journal, 18, http://dx.doi.org/10.1093/ckj/sfaf001

Perkovic V; Barratt J; Rovin B; Kashihara N; Maes B; Zhang H; Trimarchi H; Kollins D; Papachristofi O; Jacinto-Sanders S; Merkel T; Guerard N; Renfurm R; Hach T; Rizk DV, 2025, 'Alternative Complement Pathway Inhibition with Iptacopan in IgA Nephropathy', New England Journal of Medicine, 392, pp. 531 - 543, http://dx.doi.org/10.1056/NEJMoa2410316

Heerspink HJL; Agarwal R; Bakris GL; Cherney DZI; Lam CSP; Neuen BL; Sarafidis PA; Tuttle KR; Wanner C; Brinker MD; Dizayee S; Kolkhof P; Schloemer P; Vesterinen P; Perkovic V; Bittar J; Zaidman CJ; Cluigt N; Hominal M; Aguerre P; Halac F; Gelersztein E; Arriola M; Maldonado R; Chahin M; Packham D; Lee D; Pedagogos E; Foote C; Badve S; Hawley C; Chen J; Gray N; Speeckaert M; Labriola L; Doubel P; Maes B; Claes K; Dubois B; Dimitrova I; Vutova T; Ilchev S; Stamova S; Ivanova Y; Vasileva A; Chen X; Tang S; Xu X; Liu B; He W; He Y; Liu F; Wang C; Chen L; Niu J; Wang D; Luo P; Xia Y; Jiang G; Luo Q; Wang F; Chen M; Lin H; Yan R; Li Y; Chen Q; Dong J; Xiong F; Long H; Cheng H; Li Y; Du J; Liu F; Chen Q; Lu W; Chen C; Wang J; Liu L; Yang M; Long G; Shi Y; Li W; Yang X; Yang A; Li J; Meng X; Prazny M; Hornova L; Bucek P; Majernikova M; Wirth J; Rehorova J; Hornum M; Bech J; Lindhardt M; Hansen D; Mortensen L; Juhl C; Boletis I; Papadopoulou D, 2025, 'Design and baseline characteristics of the Finerenone, in addition to standard of care, on the progression of kidney disease in patients with Non-Diabetic Chronic Kidney Disease (FIND-CKD) randomized trial', Nephrology Dialysis Transplantation, 40, pp. 308 - 319, http://dx.doi.org/10.1093/ndt/gfae132

Kotwal SS; Perkovic V, 2025, 'Effects of Semaglutide on CKD in Patients With Type 2 Diabetes', Kidney International Reports, 10, pp. 287 - 290, http://dx.doi.org/10.1016/j.ekir.2024.11.1365

HA JT; FLETCHER RA; ARNOTT C; JUN MIN; KOTWAL SS; PERKOVIC V; BADVE SV; NEUEN BL, 2025, 'Albuminuria, Kidney Function and Heart Failure Risk in Type 2 Diabetes: Participant-level Pooled Analysis from the CANVAS Program and CREDENCE Trial', Journal of Cardiac Failure, http://dx.doi.org/10.1016/j.cardfail.2025.05.021

Badve SV; Bilal A; Lee MMY; Sattar N; Gerstein HC; Ruff CT; McMurray JJV; Rossing P; Bakris G; Mahaffey KW; Mann JFE; Colhoun HM; Tuttle KR; Pratley RE; Perkovic V, 2025, 'Effects of GLP-1 receptor agonists on kidney and cardiovascular disease outcomes: a meta-analysis of randomised controlled trials', Lancet Diabetes and Endocrinology, 13, pp. 15 - 28, http://dx.doi.org/10.1016/S2213-8587(24)00271-7

Kim D; Neuen BL; Perkovic V; Wong MG, 2025, 'Effects of Therapies on Proteinuria and Estimated Glomerular Filtration Rate in IgA Nephropathy: Meta-Analysis of Randomized Trials', Clinical Journal of the American Society of Nephrology, http://dx.doi.org/10.2215/CJN.0000000839

Shi S; Roberts ISD; Wang Z; Jiang L; Tang C; Wang J; Lv J; Wong MG; Barbour SJ; Perkovic V; Cattran D; Zhang H, 2025, 'Predictive Value of the Oxford Classification for the Effect of Glucocorticoid Therapy in IgA Nephropathy', Journal of the American Society of Nephrology, http://dx.doi.org/10.1681/ASN.0000000796

Nguyen TN; Yu J; Perkovic V; Arnott C; Lindley RI, 2025, 'REPLY: The Assessment Approach of Frailty May Influence Its Prognostic Impact Amidst Clinical Trials', Journal of the American Geriatrics Society, http://dx.doi.org/10.1111/jgs.19598

Zan J; Li J; Wong MG; Kim D; Shi S; Monaghan H; Perkovic V; Lv J; Zhang H, 2025, 'Role of Systemic Glucocorticoids in Reducing IgA and Galactose-Deficient IgA1 Levels in IgA Nephropathy', Clinical Journal of the American Society of Nephrology, http://dx.doi.org/10.2215/CJN.0000000816

Talbot B; Davies S; Burman J; Ritchie A; Snelling P; Lynch S; Park Y; Jones B; Garvey V; Jaure A; Jardine M; Perkovic V; Gallagher M; Brandwood A; Kaur N; Knight J, 2025, 'The Point-of-Care Peritoneal Dialysis System Early Evaluation Study (POC-PDEE): A pilot proof-of-principal study of the Ellen Medical Devices Point-of-Care affordable peritoneal dialysis system', Peritoneal Dialysis International, 45, pp. 52 - 56, http://dx.doi.org/10.1177/08968608231209850

Enríquez AJ; Mahaffey KW; Tuttle K; Baeres FMM; Bakris G; Idorn T; Perkovic V; Rasmussen IKB; Rasmussen S; Rossing P; Sokareva E; Mann J; Pratley R, 2025, 'CO-025. RESULTADOS CARDIOVASCULARES CON SEMAGLUTIDA EN FUNCIÓN DEL ESTADO BASAL DE LA ENFERMEDAD RENAL CRÓNICA EN PARTICIPANTES CON DIABETES TIPO 2 Y ENFERMEDAD RENAL CRÓNICA: RESULTADOS DEL ENSAYO FLOW', Endocrinología, Diabetes y Nutrición, 72, pp. 15 - 15, http://dx.doi.org/10.1016/s2530-0164(25)00132-6

Perkovic V; Barratt J; Lafayette R; Liew A; Suzuki Y; Carroll K; Cheung CK; Tesař V; Trimarchi H; Wong MG; Zhang H; Xia J; Fajardo C; Shah L; Hafkin J; Rizk DV, 2025, 'Evaluating Sibeprenlimab in IgA Nephropathy - Rationale and Baseline Data from the VISIONARY Trial', Kidney International Reports, http://dx.doi.org/10.1016/j.ekir.2025.09.031

Varas IJ; Perkovic V; Tuttle KR; Rossing P; Mahaffey KW; Mann J; Bakris G; Baeres FM; Idorn T; Bosch-Traberg H; Lausvig NL; Pratley R, 2025, 'P-190. ENSAYO FLOW: EFECTO DE SEMAGLUTIDA EN PERSONAS CON ENFERMEDAD RENAL CRÓNICA Y DIABETES TIPO 2', Endocrinología, Diabetes y Nutrición, 72, pp. 76 - 77, http://dx.doi.org/10.1016/s2530-0164(25)00253-8

Odler B; Riedl R; Geetha D; Szpirt WM; Hawley C; Uchida L; Wallace ZS; Walters G; Muso E; Tesar V; Pusey CD; Little MA; Merkel PA; Walsh M; Jayne DRW; Kronbichler A; PEXIVAS Investigators , 2025, 'The effects of plasma exchange and glucocorticoids on early kidney function among patients with ANCA-associated vasculitis in the PEXIVAS trial.', Kidney Int, 107, pp. 558 - 567, http://dx.doi.org/10.1016/j.kint.2024.11.029

Kotwal S; Jeyaruban A; Bose B; Lee V; Jardine M; MALLAWARCHCHI A; Ritchie A; Wong M-G; Makris A; Badve S; Siriwardana A; Yong K; Perkovic V, 2025, 'WCN25-1567 Glomerular disease registry and Biobank (GRIT)– design and baseline results', Kidney International Reports, 10, pp. S196 - S197, http://dx.doi.org/10.1016/j.ekir.2024.11.382

Kotwal S; Perkovic V; Jardine M; Vart P; Wheeler D; de Boer I; Zhang H; Hou FF; Sugawara Y; De Nicola L; Gorriz J; Heerspink H, 2025, 'WCN25-1572 DESIGN AND BASELINE CHARACTERISTICS OF THE GLOBAL KIDNEY PATIENT TRIALS NETWORK', Kidney International Reports, 10, pp. S287 - S288, http://dx.doi.org/10.1016/j.ekir.2024.11.535

Tuttle K; Arici M; Arslan EG; Bellary S; Idorn T; Ji L; Kamenov Z; Kashihara N; Mann J; Mahaffey K; Perkovic V; Rasmussen S; Rossing P; Schytz PA; Sreenivasamurthy L; Pratley R, 2025, 'WCN25-1900 Clinical and Safety Outcomes of Semaglutide by CKD Severity in the FLOW trial', Kidney International Reports, 10, pp. S770 - S770, http://dx.doi.org/10.1016/j.ekir.2024.11.1358

Lafayette R; Trimarchi H; Barratt J; Carroll K; Tesar V; Zhang H; Suzuki Y; Liew A; Wong MG; Shah L; Xia J; Fajaro C; Hafkin J; Perkovic V, 2025, 'WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY', Kidney International Reports, 10, pp. S158 - S159, http://dx.doi.org/10.1016/j.ekir.2024.11.328

Rizk D; Lafayette R; Trimarchi H; Barratt J; Carroll K; Tesar V; Zhang H; Suzuki Y; Liew A; Wong MG; Shah L; Xia J; Fajaro C; Hafkin J; Perkovic V, 2025, 'WCN25-499 PATIENT BASELINE CHARACTERISTICS IN THE ONGOING PHASE 3 VISIONARY TRIAL: A RANDOMIZED, PLACEBO-CONTROLLED STUDY OF SIBEPRENLIMAB FOR IMMUNOGLOBULIN A NEPHROPATHY (vol 10, pg S158, 2025)', KIDNEY INTERNATIONAL REPORTS, 10, pp. 2892 - 2892

Kollins D; Papachristofi O; Hach T; Valentin M-A; Merkel T; Renfurm R; Perkovic V, 2025, 'WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY', Kidney International Reports, 10, pp. S177 - S177, http://dx.doi.org/10.1016/j.ekir.2024.11.358

Perkovic V; Rizk D; Kollins D; Papachristofi O; Hach T; Valentin M-A; Merkel T; Renfurm R, 2025, 'WCN25-716 EFFECT OF IPTACOPAN ON PROTEINURIA AND COMPLEMENT BIOMARKERS IN IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS OF THE PHASE 3 APPLAUSE-IgAN STUDY (vol 10, pg S177, 2025)', KIDNEY INTERNATIONAL REPORTS, 10, pp. 2890 - 2890

Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Schmouder R; Kulmatycki K; Renfurm R; Perkovic V, 2025, 'WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS', Kidney International Reports, 10, pp. S183 - S184, http://dx.doi.org/10.1016/j.ekir.2024.11.362

Perkovic V; Rizk D; Kollins D; Papachristo O; Hach T; Jacinto-Sanders S; Merkel T; Schmouder R; Kulmatycki K; Renfurm R, 2025, 'WCN25-797 SAFETY AND EFFICACY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN) WITH BASELINE eGFR 20-<30 mL/MIN: PHASE 3 APPLAUSE-IgAN SUBCOHORT RESULTS (vol 10, pg S183, 2025)', KIDNEY INTERNATIONAL REPORTS, 10, pp. 2890 - 2890

Kollins D; Papachristofi O; Hach T; Jacinto-Sanders S; Merkel T; Renfurm R; Perkovic V, 2025, 'WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY', Kidney International Reports, 10, pp. S184 - S184, http://dx.doi.org/10.1016/j.ekir.2024.11.363

Rizk D; Kollins D; Papachristo O; Hach T; Jacinto-Sanders S; Merkel T; Renfurm R; Perkovic V, 2025, 'WCN25-799 EFFICACY AND SAFETY OF IPTACOPAN IN PATIENTS WITH IgA NEPHROPATHY (IgAN): INTERIM ANALYSIS (IA) OF THE PHASE 3 APPLAUSE-IgAN STUDY( vol 10, pg S184 , 2025)', KIDNEY INTERNATIONAL REPORTS, 10, pp. 2890 - 2890

Perkovic V; Tuttle K; Sattar N; Lincoff AM; Navar AM; Marx N; Hvelplund A; Baeres FMM; Engelmann MD; Hovingh GK; Ridker PM, 2025, 'WCN25-888 DESIGN OF THE ZEUS TRIAL: INTERLEUKIN 6 INHIBITION WITH ZILTIVEKIMAB FOR CARDIOVASCULAR PROTECTION IN CHRONIC KIDNEY DISEASE', Kidney International Reports, 10, pp. S767 - S768, http://dx.doi.org/10.1016/j.ekir.2024.11.1354

Kotwal SS; Perkovic V; Jardine MJ; Kim D; Shah NA; Lin E; Coggan S; Billot L; Vart P; Wheeler DC; De Boer IH; Zhang H; Hou FF; Sugawara Y; Marion J; Lewis RJ; Berry LR; McGlothlin A; Jha V; De Nicola L; Gorriz JL; Heerspink HJL, 2024, 'The Global Kidney Patient Trials Network and the CAPTIVATE Platform Clinical Trial Design: A Trial Protocol', JAMA Network Open, 7, http://dx.doi.org/10.1001/jamanetworkopen.2024.49998

Heerspink HJL; Perkovic V; Tuttle KR; Pergola PE; Mahaffey KW; Patel UD; Ishida JH; Kuo A; Chen F; Kustra R; Petrovic V; Rossing P; Kashihara N; Chertow GM, 2024, 'Selonsertib in Patients with Diabetic Kidney Disease: A Phase 2b Randomized Active Run-In Clinical Trial', Journal of the American Society of Nephrology, 35, pp. 1726 - 1736, http://dx.doi.org/10.1681/ASN.0000000000000444

Neuen BL; Ostrominski JW; Claggett B; Beldhuis IE; Chatur S; McCausland FR; Badve SV; Arnott C; Heerspink HJL; Jun M; Falster M; de Oliveira Costa J; Pollock C; Jardine MJ; Mahaffey KW; Perkovic V; Solomon SD; Vaduganathan M, 2024, 'Bidirectional Relationship Between Kidney Disease Progression and Cardiovascular Events in Type 2 Diabetes', Journal of the American College of Cardiology, 84, pp. 2246 - 2250, http://dx.doi.org/10.1016/j.jacc.2024.08.006

Neuen BL; Fletcher RA; Heath L; Perkovic A; Vaduganathan M; Badve SV; Tuttle KR; Pratley R; Gerstein HC; Perkovic V; Heerspink HJL, 2024, 'Cardiovascular, Kidney, and Safety Outcomes with GLP-1 Receptor Agonists Alone and in Combination with SGLT2 Inhibitors in Type 2 Diabetes: A Systematic Review and Meta-Analysis', Circulation, 150, pp. 1781 - 1790, http://dx.doi.org/10.1161/CIRCULATIONAHA.124.071689

Perkovic V; Tuttle KR; Pratley R, 2024, 'The authors reply: Semaglutide for Chronic Kidney Disease in Type 2 Diabetes', New England Journal of Medicine, 391, pp. 1757, http://dx.doi.org/10.1056/NEJMc2410532

Back to profile page